Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Sushil Patel
Person

Sushil Patel

Tracked across 2 events · 73 articles · First seen Jun 26, 2026 · Last active Aug 14, 2026

Sentiment
-35
Attention
6
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
4 -70
Regulatory
Replimune Securities Class Action Over FDA Rejection
Replimune Group, a biotechnology company, faces multiple securities class action lawsuits filed by several law firms, including Pomerantz LLP, Bronstein, Gewirtz & Grossman, LLC, Levi & Korsinsky, and Schall Brown & Schwartz LLP, on behalf…
Impact: Sushil Patel, CEO of Replimune, is named as an individual defendant in the class actions. Allegations of misleading statements and failure to disclose FDA concerns could lead to personal liability.
Jul 29, 2026 · 65 articles
6 0
Regulatory
FDA Accepts Replimune RP1 BLA Resubmission
Impact: Sushil Patel, as CEO of Replimune Group, expressed satisfaction with the United States — Food and Drug Administration's urgency in reviewing the RP1 BLA, highlighting the company's perspective on the regulatory process.
Jun 26, 2026 · 8 articles
Key Actions (1)
80 Sushil Patel named as defendantReplimune Securities Class...
ERGEN INTELLIGENCE
Track Sushil Patel live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.